Sterling Investment Advisors Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sterling Investment Advisors Ltd. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,762 shares of the biopharmaceutical company’s stock after acquiring an additional 715 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in Regeneron Pharmaceuticals were worth $2,680,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. Allworth Financial LP now owns 709 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 48 shares in the last quarter. Frank Rimerman Advisors LLC lifted its position in Regeneron Pharmaceuticals by 3.5% in the third quarter. Frank Rimerman Advisors LLC now owns 597 shares of the biopharmaceutical company’s stock valued at $628,000 after acquiring an additional 20 shares during the last quarter. J.W. Cole Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 11.5% in the third quarter. J.W. Cole Advisors Inc. now owns 802 shares of the biopharmaceutical company’s stock valued at $843,000 after acquiring an additional 83 shares during the last quarter. Cavalier Investments LLC lifted its position in Regeneron Pharmaceuticals by 5.8% in the third quarter. Cavalier Investments LLC now owns 2,519 shares of the biopharmaceutical company’s stock valued at $2,648,000 after acquiring an additional 138 shares during the last quarter. Finally, FCG Investment Co lifted its position in Regeneron Pharmaceuticals by 26.0% in the third quarter. FCG Investment Co now owns 1,024 shares of the biopharmaceutical company’s stock valued at $1,076,000 after acquiring an additional 211 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. TD Cowen reduced their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ REGN opened at $713.25 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a market capitalization of $77.98 billion, a PE ratio of 18.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm’s 50-day moving average is $699.17 and its two-hundred day moving average is $878.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.86 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.